<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Furosemide - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../style.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Furosemide</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../index.html">Home</a>
        <a class="btn small" href="../medications.html">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Cardiac / Vascular</div>
      <h1>Furosemide</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Furosemide 20mg Tablets</li>
          <li>Furosemide 10mg/mL Injection 2mL</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <p><strong>Acute pulmonary edema / acute heart failure with volume overload (protocol-dependent)</strong></p>
        <ul>
          <li>IV: 20–40 mg IV; reassess response (BP, work of breathing, urine output) and repeat/escalate per local protocol</li>
        </ul>
        <p><strong>Peripheral edema/volume overload (non-emergent)</strong></p>
        <ul>
          <li>PO: 20–40 mg PO; titrate per clinical response and local guidance</li>
        </ul>
        <p><strong>Adjunct in hyperkalemia (if producing urine; protocol-dependent)</strong></p>
        <ul>
          <li>IV or PO dosing per local protocol as part of a broader hyperkalemia pathway (not as monotherapy)</li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Volume overload/edema (e.g., heart failure) and pulmonary edema (protocol-dependent)</li>
          <li>Adjunct diuresis in selected scenarios where fluid removal is desired (provider/protocol-directed)</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Anuria or severe dehydration/hypovolemia</li>
          <li>Hypotension/shock (may worsen)</li>
          <li>Significant electrolyte depletion (especially hypokalemia, hyponatremia, hypomagnesemia)</li>
          <li>Renal dysfunction: use caution; monitor response and renal function when possible</li>
          <li>Ototoxicity risk with high doses/rapid IV administration (dose/rate dependent)</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>Hypotension, dizziness, dehydration</li>
          <li>Electrolyte abnormalities (↓K, ↓Na, ↓Mg) and metabolic alkalosis</li>
          <li>Worsening renal function (pre-renal azotemia) if over-diuresed</li>
          <li>Ototoxicity (rare; higher risk with rapid/high-dose IV)</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <p><strong>IV formulation: 10 mg/mL; stocked 2 mL = 20 mg total</strong></p>
        <ul>
          <li>Administer IV slowly and reassess frequently (BP, symptoms, urine output)</li>
        </ul>
        <p><strong>PO tablets: 20 mg</strong></p>
        <ul>
          <li>Ensure access to fluids as clinically appropriate; avoid over-diuresis</li>
        </ul>
        <p>Consider potassium strategy per local protocol if ongoing diuresis planned and K is available onboard</p>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>BP, HR, SpO2; clinical work of breathing (if pulmonary edema)</li>
          <li>Urine output and hydration status</li>
          <li>Electrolytes and renal function when available (K/Na/Mg/creatinine)</li>
          <li>Daily weights/fluid balance if prolonged therapy</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>Lab limitations: dose conservatively and rely on clinical reassessment (BP, orthostasis, urine output, symptoms)</li>
          <li>Avoid over-diuresis in heat/exertion/limited water intake environments</li>
          <li>Document dose/time and response; track cumulative dosing during prolonged cases</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (furosemide injection): https://pdf.hres.ca/dpd_pm/00065980.PDF</li>
          <li>BCEHS drug monograph (furosemide): https://handbook.bcehs.ca/drug-monographs/furosemide/</li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
